For example, JAK/STAT pathway inhibition can be considered as a promising target for the treatment of vitiligo, a complex skin depigmentation disease that involves multiple pathogenetic mechanisms, including genetic predisposition, oxidative mechanisms and environmental factors, which culminate in the destruction of melanocytes by CD8+ cytotoxic T cells (176). Here, CD8A is linked to vitiligo.